Brain Sciences,
Год журнала:
2025,
Номер
15(2), С. 161 - 161
Опубликована: Фев. 6, 2025
Background/Objectives:
Non-response
to
initial
treatment
options
for
major
depressive
disorder
(MDD)
is
a
common
clinical
challenge
with
profound
deleterious
impacts
affected
patients.
Few
treatments
have
received
regulatory
approval
treatment-resistant
depression
(TRD).
Methods:
A
systematic
search
of
United
States
and
European
Union
trials
registries
was
conducted
identify
Phase
II,
III,
or
IV
trials,
last
update
posted
on
after
1
January
2020,
that
were
evaluating
medications
TRD.
For
both
the
US
EU
registries,
condition
term
"treatment
resistant
depression"
associated
lower-level
terms
(per
registry
protocol)
used.
registry,
secondary
using
"depressive
disorders"
modifying
"inadequate"
also
performed
capture
registrations
not
tagged
as
Two
additional
searches
in
"suicide"
"anhedonia"
transdiagnostic
targets
investigational
medications.
Trials
categorized
based
primary
mechanism
action
trial's
medication.
Results:
Fifty
TRD,
20
anhedonia,
25
suicide
identified.
Glutamate
system
modulation
currently
most
compounds
development,
including
antagonists
allosteric
modulators
NMDA
receptors,
AMPA
metabotropic
type
2/3
glutamate
intracellular
effector
molecules
downstream
signaling.
Psychedelics
seen
greatest
surge
among
mechanistic
past
5
years,
however,
psilocybin
particular
garnering
significant
attention.
Other
mechanisms
included
GABA
modulators,
monoamine
anti-inflammatory/immune-modulating
agents,
an
orexin
2
receptor
antagonist.
Conclusions:
These
investigations
offer
substantial
promise
more
efficacious
potentially
personalized
medication
approaches
Challenges
detecting
efficacy
TRD
include
heterogeneity
within
population
stemming
from
presumed
variety
biological
dysfunctions
underlying
disorder,
comorbid
disorders,
chronic
psychosocial
stressors,
enduring
effects
prior
serotonergic
antidepressant
treatments.
JAMA Psychiatry,
Год журнала:
2023,
Номер
80(7), С. 743 - 743
Опубликована: Май 31, 2023
Importance
Mounting
evidence
supports
the
role
of
spiritual,
existential,
religious,
and
theological
components
in
mediating
psychedelic-assisted
therapy,
yet
integration
these
elements
into
clinical
setting
is
lagging
Observations
Although
therapy
commonly
produces
spiritually,
existentially,
religiously,
or
theologically
relevant
experiences
for
patients,
have
not
been
systematically
integrated
psychotherapies
that
accompany
therapeutic
uses
psychedelics.
As
a
key
feature
potential
mediator
effects,
evidence-based
therapies
should
include
topics
treatment
model.
Research
across
multiple
diagnostic
targets
contexts
suggests
spiritually
are
effective,
feasible,
produce
add-on
benefits
outcomes,
which
particularly
germane
to
Established
standards
psychotherapy
may
be
fruitfully
applied
therapy.
Objectives
based
on
informed
by
considerations
specific
psychedelics
recommended.
Conclusions
Relevance
Spiritual,
topics’
needed
ensure
culturally
competent,
aligned
with
highest
care.
Neglecting
address
can
detract
from
cultural
competence,
contribute
risks
potentially
undermine
success.
American Journal of Psychiatry,
Год журнала:
2025,
Номер
182(1), С. 21 - 32
Опубликована: Янв. 1, 2025
During
the
past
decade,
there
has
been
extraordinary
public,
media,
and
medical
research
interest
in
psychedelics
as
promising
therapeutics
for
difficult-to-treat
psychiatric
disorders.
Short-term
controlled
trial
data
suggest
that
certain
are
effective
safe
treatment
of
major
depressive
disorder,
treatment-resistant
depression,
posttraumatic
stress
disorder.
Preliminary
evidence
also
supports
efficacy
other
disorders
(e.g.,
tobacco
alcohol
use
disorders).
Notwithstanding
promise
psychedelics,
concerns
have
arisen
with
respect
to
interpretability
translatability
study
results.
For
example,
aspects
related
short-
long-term
safety,
abuse
liability,
essentiality
psychedelic
"trip"
psychological
support
are,
inter
alia,
insufficiently
characterized
agents.
The
overarching
aims
this
overview
1)
review
methodological
affect
inferences
interpretation
extant
studies
disorders,
2)
provide
guidance
future
development
psychiatry,
critical
clinical
implementation.
Frontiers in Psychology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 5, 2025
There
is
notable
controversy
about
the
role
of
psychotherapy
in
clinical
trials
psychedelic-assisted
therapy
(PAT).
This
heated
and
perpetually
evolving
debate
informs
questions
such
as
how
much
should
accompany
a
psychedelic
intervention
(Marseille
et
al.,
2022),
what
type
most
effectively
complements
administration
(Cavarra
2022;Yaden
even
whether
always
be
included
(Goodwin
2023;Earleywine
2024;Schenberg,
2024).
Recent
events,
namely
rejection
by
Food
Drug
Administration
(FDA)
Lykos
Therapeutics'
application
to
approve
MDMA-assisted
(MDMA-AT)
treatment
for
PTSD,
has
brought
forth
some
intricacies
within
this
debate.
That
governing
body's
pharmacological
agents,
not
psychotherapies.
The
FDA
was
likely
unfamiliar
with
complication
including
MDMA-AT,
rather
than
evaluating
MDMA
standalone
intervention.
highlights
novelty
PAT
medicalized
settings,
underscores
bona
fide
necessary
component
drug
administration.From
our
perspective,
unique
psychiatric
that
it
genuinely
combined
treatment,
involving
substance
psilocybin
or
context
psychotherapy.
Thus,
synergizes
elements
enhancement
along
psychological
relational
learning
healing.
psychedelics
seems
potentiate
cognitive,
emotional,
behavioral
change
help
more
effective
2022;Grunder
2024;Nayak
&
Johnson,
2021).
Additionally,
like
psychotherapies,
emerging
evidence,
consistent
body
evidence
literature,
suggesting
quality
relationship
between
therapists
patients
critically
important
success
(Levin
2024;Murphy
2022;Zeifman
emotional
impact
real
developed
crucial
patient's
healing,
perfunctory
safety
protocol
nor
peripheral
afterthought.We
champion
essential
arc
helping
attain
meaningful
relief
from
their
distress,
we
encourage
rigorous
scientific
examination
which
types
doses
may
optimize
delivery
PAT.Commented
[JZ1]:
word
erroneously
title
article,
"auto-read"
being
part
title.
I
am
deleting
here
paper.While
researchers
support
inclusion
2022;Deckel
2024;Earleywine
2024;Schenberg
2024),
others
have
made
case
administration.
Goodwin
al.
(2023)
advance
argument,
stating
there
minimal
confirm
belief
truly
form
enhanced
catalyzed
They
suggest
administration,
safety,
often
all
produce
many
suffering
serious
mental
health
conditions,
configuration
general
study
effects
on
psychosocial
health.They
first
claim
used
been
nondirective
counseling,
counseling
an
evidence-based
conditions
targeted
PAT,
treatment-resistant
depression,
use
disorders.
Our
perspective
la
carte
platter,
"best"
constructed
extracting
other
non-psychedelic
treatments
(like
psychotherapies)
forcing
them
into
framework
PAT.
Rather
cobbling
together
specific
ingredients
package,
advocate
therapies
are
efficacious
when
delivered
concert
applied
setting.
If
preliminary
could
treat
condition,
might
further
improve
outcome
pair
thoughtfully-selected
approaches,
principles,
techniques
understood
efficacious?
We
will
know
unless
phenomenon.
As
stated
Earleywine
(2024),
"only
data
can
answer
question.
A
trial
compare
groups
without
extensive
preparation
integration."
same
true
regarding
position
well-trained
facilitators
ensure
allow
patient
fully
immersed
experience,
but
no
assumptions
improving
efficacy.
Indeed,
assumption
made,
only
thoroughly
studying
issue
able
come
complete
understanding,
preventing
urge
make
assumptions.The
authors
assert
complex
interactions
facilitators,
kinds
exemplify
forms
psychotherapy,
impediment
research;
they
complicate
efforts
determine
therapeutic
effect
psychedelic,
unregulated,
lead
ethical
violations.
It
becomes
difficult
account
placebo
phenomenon
expectancy,
patient-therapist
mutually
unblind
condition.
But
entire
-the
set
setting,
behavior
therapists,
interventions,
relationships
-is
contributor
outcome.
cannot
completely
isolate
Separating
out
us
understand
each
aspect
limits
understanding
interaction
these
distinct
avenues,
(Decker
similar
conventional
aspects
randomized
dismantled,
randomize
two
different
modalities
offer
components
unitary
(e.g.
randomizing
receiving
CBT
receive
cognitive
restructuring
activation
only),
therapist's
empathy
ability
identify
agree
upon
goals
patients)
so
integral
paradigm
would
unethical
unfeasible
remove
trial.
Process-oriented
metaanalytic
research
assisted
elements,
absent
randomizable
condition
(Norcross
Lambert,
2011).PAT
routinely
include
al.'s
concerns
addressed
through
methodologically
and,
appropriate
protocols,
training,
regulation,
adherence
monitoring
minimize
risk
violations
harm
patients.Further
complicating
discussion
psychotherapy's
type(s)
employed.
Current
limited
modality
particular
diagnoses
populations
patients,
arguments
put
highlighting
approaches
(Brennan
Belser,
2022;Sloshower
2020;Yaden
2022).Yaden
(
2022)
argue
cognitive-behavioral
(CBT)
default
citing
its
robust
base
natural
match
interventions
While
understandable
temptation
clinicians
provide
orderly,
structured
can,
problems
argument.
order
prevent
premature
foreclosure
exploration
potentially
usefully
PAT.The
high
level
congruence
concepts
Some
concepts,
sessions
self-monitoring,
indeed
helpful
demonstrate
anything
inherently
sets
apart
any
default.
Other
referenced
authors,
present
moment
awareness,
mindfulness,
reflective
listening,
CBT.
roots
humanistic-existential
psychodynamic
therapy,
well
Eastern
wisdom
traditions,
employed
varieties
And
yet
suggestions,
attempting
utilize
during
session,
actually
conflict
multidimensional
non-ordinary
states
consciousness
engender.
Psychedelic
predict,
open
process.
Attempts
"control"
experience
session
difficult,
hinder
effectiveness
(Luoma
2019).
In
typically
follow
process,
largely
self-determined
sometimes
openended.
Flexibility
therapist
key.
practice
CBT,
design,
does
open-endedness
-rather,
identifies
focus
clinician.
Excessive
open-ended
process
viewed
focus,
hijacking
objective.
rationale
makes
sense
difficult-to-predict
contours
session.Most
concerningly,
authors'
suggestion
create
self-fulfilling
prophecy.
Assuming
approach
prematurely
forecloses
inquiry
develop
best
practices
fails
acknowledge
potential
those
commonly
historically
paired
humanistic,
depthoriented,
somatic,
transpersonal
Studies
show
benefits
never
conducted,
far
lower
number
studies
pairing
imbalance
accrual
sustain
false
narrative
one
school
somehow
innately
superior
another,
replicated
finding
yield
equivalent
compared
only,
if
helpful,
whom
helpful.
unnecessarily
trying
disassemble
known
synergistic
produced
potentiation
concurrent
processing
results
high-quality
therapy.In
addition
thorough
synergize
accomplished
head-to-head
corresponding
differing
theoretical
orientations
quantities
Researchers
also
survey
consumers
who
interested
gleaning
needs.
especially
minoritized
harmed
whose
needs
prioritized
(Straus
value
strongly
feel
human
element
must
preserved
deeply
examined.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(2), С. 1329 - 1329
Опубликована: Янв. 10, 2023
The
need
to
identify
effective
therapies
for
the
treatment
of
psychiatric
disorders
is
a
particularly
important
issue
in
modern
societies.
In
addition,
difficulties
finding
new
drugs
have
led
pharmacologists
review
and
re-evaluate
some
past
molecules,
including
psychedelics.
For
several
years
there
has
been
growing
interest
among
psychotherapists
psilocybin
or
lysergic
acid
diethylamide
obsessive-compulsive
disorder,
depression,
post-traumatic
stress
although
results
are
not
always
clear
definitive.
fact,
mechanisms
action
psychedelics
yet
fully
understood
molecular
aspects
be
well
defined.
Thus,
this
aims
summarize
ethnobotanical
uses
best-known
psychedelic
plants
pharmacological
main
active
ingredients
they
contain.
Furthermore,
an
up-to-date
overview
structural
computational
studies
performed
evaluate
affinity
binding
modes
biologically
relevant
receptors
ibogaine,
mescaline,
N,N-dimethyltryptamine,
psilocin,
presented.
Finally,
most
recent
clinical
evaluating
efficacy
molecules
discussed
compared
with
already
used
therapy.
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Фев. 8, 2024
Abstract
Preparing
participants
for
psychedelic
experiences
is
crucial
ensuring
these
are
safe
and,
potentially
beneficial.
However,
there
currently
no
validated
measure
to
assess
the
extent
which
well-prepared
such
experiences.
Our
study
aimed
address
this
gap
by
developing,
validating,
and
testing
Psychedelic
Preparedness
Scale
(PPS).
Using
a
novel
iterative
Delphi-focus
group
methodology
(‘DelFo’),
followed
qualitative
pre-test
interviews,
we
incorporated
perspectives
of
expert
clinicians/researchers
users
generate
items
scale.
Psychometric
validation
PPS
was
carried
out
in
two
large
online
samples
(N
=
516;
N
716),
scale
also
administered
before
after
5–7-day
psilocybin
retreat
46).
Exploratory
confirmatory
factor
analysis
identified
four
factors
from
20-item
PPS:
Knowledge-Expectations,
Intention-Preparation,
Psychophysical-Readiness,
Support-Planning.
The
demonstrated
excellent
reliability
(ω
0.954)
evidence
supporting
convergent,
divergent
discriminant
validity
obtained.
Significant
differences
between
those
scoring
high
low
(on
preparedness)
experience
were
found
on
measures
mental
health/wellbeing
outcomes
assessed
experience,
suggesting
that
has
predictive
utility.
By
prospectively
measuring
modifiable
pre-treatment
preparatory
behaviours
attitudes
using
PPS,
it
may
be
possible
determine
whether
participant
generated
appropriate
‘set’
therefore
likely
benefit
or
at
least,
less
harmed.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(6), С. 1727 - 1727
Опубликована: Март 17, 2024
Major
Depressive
Disorder
(MDD)
is
one
of
the
most
disabling
diseases
in
world.
MDD
traditionally
diagnosed
based
on
a
patient’s
symptoms,
which
can
lead
to
misdiagnosis.
Although
pathogenic
mechanisms
are
unknown,
several
studies
have
identified
mitochondrial
dysfunction
as
central
factor
onset
and
progression
MDD.
In
context
MDD,
alterations
metabolism
imbalances
energy
production
oxidative
stress,
contributing
disorder´s
underlying
pathophysiological
mechanisms.
Consequently,
identification
key
biomarker
for
early
accurate
diagnosis
represents
significant
challenge.
Faced
with
limits
traditional
treatments
antidepressants,
new
pharmacological
therapeutic
targets
being
investigated
such
ketamine/esketamine,
psychedelics,
or
anti-inflammatories.
All
these
drugs
show
potential
antidepressant
effects
due
their
speed
action
ability
modulate
neuroplasticity
and/or
motor
processing.
parallel,
non-pharmacological
studied,
like
Transcranial
Magnetic
Stimulation
(TMS)
Deep
Brain
(DBS),
recognized
neuronal
activity
offer
treatment
alternatives.
As
cellular
directly
related
respiration,
aim
this
review
examining
link
between
assessing
how
biomarkers
could
provide
more
objective
precise
diagnostic
tool,
exploring
other
addition
specific
focus
emerging
targets.
Finally,
detailed
analysis
strengths,
weaknesses,
opportunities,
threats
approaches
was
carried
out,
highlighting
challenges
that
must
be
addressed.
American Journal of Psychiatry,
Год журнала:
2025,
Номер
182(1), С. 33 - 46
Опубликована: Янв. 1, 2025
Unlike
classical
antidepressants,
psychedelics
such
as
psilocybin
have
been
shown
to
induce
a
rapid
antidepressant
response.
In
the
wake
of
this
development,
interest
has
emerged
in
ultra-fast,
short-acting
5-methoxy-N,N-dimethyltryptamine
(5-MeO-DMT)
and
N,N-dimethyltryptamine
(DMT)
with
expectation
that
these
can
produce
effects
following
an
intense
but
brief
psychedelic
intervention.
The
current
paper
reviews
clinical
pharmacology
5-MeO-DMT
DMT
their
potential
benefits
challenges
treatment
depression.
Both
compounds
display
affinities
for
variety
monoamine
receptors
transporters,
mostly
so
serotonergic
(5HT)
receptors,
including
5HT